Yusef Dawood, Gonzalez Blanca E, Foster Charles B, Goldfarb Johanna, Saracusa Carla, Worley Sarah, Sabella Camille
*Department of Pediatrics, Jordan University of Science and Technology, Irbid, Jordan; †Center for Pediatric Infectious Diseases, Cleveland Clinic Children's, Cleveland, Ohio; and ‡Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio.
Pediatr Infect Dis J. 2017 Jan;36(1):50-52. doi: 10.1097/INF.0000000000001351.
We report a significantly higher occurrence of adverse events associated with prolonged courses of piperacillin-tazobactam compared with other antibacterial agents used for pediatric outpatient parenteral antimicrobial therapy. These adverse events were characterized by a constellation of clinical findings including fever, hematologic abnormalities and transaminitis. Adverse events related to piperacillin-tazobactam should be considered in patients who develop a febrile illness associated with a prolonged course of therapy.
我们报告称,与用于儿科门诊胃肠外抗菌治疗的其他抗菌药物相比,哌拉西林-他唑巴坦疗程延长时出现不良事件的发生率显著更高。这些不良事件的特征是一系列临床症状,包括发热、血液学异常和转氨酶升高。对于在治疗疗程延长后出现发热性疾病的患者,应考虑与哌拉西林-他唑巴坦相关的不良事件。